Preoperative Immune Checkpoint Inhibitor Therapy and Perioperative Cardiovascular Complications after Noncardiac Cancer Surgery: The REMIOS-ICI Study
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
This observational cohort study uses retrospective data from the REMIOS project (2013–2022) to evaluate the association between preoperative immune checkpoint inhibitor (ICI) exposure within six months and perioperative cardiovascular complications. Adult patients undergoing intermediate- to high-risk noncardiac cancer surgery are categorized into ICI-exposed and unexposed groups. Primary outcomes are 30-day myocardial injury (MINS) and major adverse cardiovascular events (MACE), with secondary outcomes of 30-day mortality and 7-day acute kidney injury. Confounding is controlled via doubly robust estimation. The study aims to clarify whether recent ICI therapy increases perioperative cardiovascular risk, informing perioperative management in this growing patient population.
Fields of Study & Subjects
Cardiac
Anesthesia and Surgical Outcomes
Cancer Immunotherapy and Biomarkers
Chemotherapy-induced cardiotoxicity and mitigation
Publication details
- Journal / source
- Open Science Framework
- Publication date
- 1 January 2026
- Language
- EN